Skip to content

Validation of a novel pre-test concept (DrugAsens®) by quantification of THC concentrations in saliva

Validation of a novel pre-test concept (DrugAsens®) by quantification of THC concentrations in saliva - Validation of the DrugAsens® pre-test

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00036203
Enrollment
10
Registered
2025-02-25
Start date
2026-10-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Regular cannabis users consume once under supervision with saliva samples taken

Interventions

Group 1: A maximum of 10 people who have already smoked cannabis / marijuana at least once a month in the past are asked to consume cannabis under medical supervision. Using the DrugAsens® sensor, sev

Sponsors

Insitut für Rechtsmedizin Essen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Anamnestically healthy, adult, cannabis-accustomed (i.e. cannabis use at least once a month) women and men of all ages and constitutional types. Regular cannabis use can be expressly accepted.

Exclusion criteria

Exclusion criteria: - Minors - Pre-existing cardiac and/or psychiatric conditions* - Pregnancy or breastfeeding* - First-time cannabis users* - Desired consumption of >500 mg cannabis per joint under study conditions - noticeable substance influence due to the consumption of (other) drugs/medication/alcohol on the day of the trial - Multiple use of cannabis during the study day *With regard to cannabis experience/pre-existing conditions/pregnancy, the selection procedure is based on the subjects' self-reporting, as the completely anonymous study design means that no personal/clinical anamnesis can be collected.

Design outcomes

Primary

MeasureTime frame
The aim of the study is to test whether the technical sensor DrugAsens® is able to deliver fully quantitative and valid results for the detection of Delta9-THC in saliva on the basis of its novel technology. The test system is expected to demonstrate high selectivity and agreement of its quantitative results in comparison to the forensically validated (chromatographic) reference method.

Secondary

MeasureTime frame
Proof of the validity of the pre-test results is a prerequisite for further developments/tests towards the routine suitability of the DrugAsens® (e.g. handling by trained laypersons etc.).

Countries

Germany

Contacts

Public ContactUta Küpper

Universitätsklinikum Essen, Institut für Rechtsmedizin

uta.kuepper@uk-essen.de+49 201 7233666

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026